Xinjiang Baihuacun Co Ltd (600721) - Total Liabilities
Based on the latest financial reports, Xinjiang Baihuacun Co Ltd (600721) has total liabilities worth CN¥284.73 Million CNY (≈ $41.66 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 600721 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Xinjiang Baihuacun Co Ltd - Total Liabilities Trend (1994–2025)
This chart illustrates how Xinjiang Baihuacun Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Xinjiang Baihuacun Co Ltd assets under control.
Xinjiang Baihuacun Co Ltd Competitors by Total Liabilities
The table below lists competitors of Xinjiang Baihuacun Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OneSpan Inc
NASDAQ:OSPN
|
USA | $113.54 Million |
|
Anhui Huaheng Biotechnology Co. Ltd. A
SHG:688639
|
China | CN¥3.36 Billion |
|
Goldcard High-Tech Co Ltd
SHE:300349
|
China | CN¥2.96 Billion |
|
Bestlink Tech Co Ltd
SHG:603206
|
China | CN¥5.51 Billion |
|
Shanghai Baosight Software Co Ltd B
SHG:900926
|
China | $10.57 Billion |
|
ACLARA RESOURCES INC.
F:JD1
|
Germany | €10.94 Million |
|
Tianjin Lisheng Pharmaceutical Co Ltd
SHE:002393
|
China | CN¥893.57 Million |
|
Hangzhou Shenhao Technology Co Ltd
SHE:300853
|
China | CN¥1.00 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Xinjiang Baihuacun Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Xinjiang Baihuacun Co Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xinjiang Baihuacun Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xinjiang Baihuacun Co Ltd (1994–2025)
The table below shows the annual total liabilities of Xinjiang Baihuacun Co Ltd from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥294.43 Million ≈ $43.08 Million |
-17.29% |
| 2024-12-31 | CN¥355.96 Million ≈ $52.09 Million |
+0.16% |
| 2023-12-31 | CN¥355.39 Million ≈ $52.01 Million |
+6.31% |
| 2022-12-31 | CN¥334.31 Million ≈ $48.92 Million |
+12.92% |
| 2021-12-31 | CN¥296.06 Million ≈ $43.32 Million |
-15.54% |
| 2020-12-31 | CN¥350.52 Million ≈ $51.29 Million |
+4.16% |
| 2019-12-31 | CN¥336.51 Million ≈ $49.24 Million |
+2.36% |
| 2018-12-31 | CN¥328.75 Million ≈ $48.11 Million |
+9.68% |
| 2017-12-31 | CN¥299.74 Million ≈ $43.86 Million |
-38.26% |
| 2016-12-31 | CN¥485.52 Million ≈ $71.05 Million |
-86.54% |
| 2015-12-31 | CN¥3.61 Billion ≈ $527.95 Million |
+13.87% |
| 2014-12-31 | CN¥3.17 Billion ≈ $463.65 Million |
+2.65% |
| 2013-12-31 | CN¥3.09 Billion ≈ $451.66 Million |
-6.86% |
| 2012-12-31 | CN¥3.31 Billion ≈ $484.92 Million |
+0.05% |
| 2011-12-31 | CN¥3.31 Billion ≈ $484.67 Million |
+9.40% |
| 2010-12-31 | CN¥3.03 Billion ≈ $443.02 Million |
+408.13% |
| 2009-12-31 | CN¥595.81 Million ≈ $87.19 Million |
+27.09% |
| 2008-12-31 | CN¥468.81 Million ≈ $68.60 Million |
+15.79% |
| 2007-12-31 | CN¥404.88 Million ≈ $59.25 Million |
+68.54% |
| 2006-12-31 | CN¥240.22 Million ≈ $35.15 Million |
-16.54% |
| 2005-12-31 | CN¥287.83 Million ≈ $42.12 Million |
-21.61% |
| 2004-12-31 | CN¥367.17 Million ≈ $53.73 Million |
-29.91% |
| 2003-12-31 | CN¥523.86 Million ≈ $76.66 Million |
+28.54% |
| 2002-12-31 | CN¥407.54 Million ≈ $59.64 Million |
+113.92% |
| 2001-12-31 | CN¥190.51 Million ≈ $27.88 Million |
-12.01% |
| 2000-12-31 | CN¥216.52 Million ≈ $31.68 Million |
+5.11% |
| 1999-12-31 | CN¥206.00 Million ≈ $30.14 Million |
+0.77% |
| 1998-12-31 | CN¥204.42 Million ≈ $29.91 Million |
+6.23% |
| 1997-12-31 | CN¥192.43 Million ≈ $28.16 Million |
-28.79% |
| 1996-12-31 | CN¥270.21 Million ≈ $39.54 Million |
+125.86% |
| 1995-12-31 | CN¥119.64 Million ≈ $17.51 Million |
+60.91% |
| 1994-12-31 | CN¥74.35 Million ≈ $10.88 Million |
-- |
About Xinjiang Baihuacun Co Ltd
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd engages in pharmaceutical research and development, clinical trials, biomedicine, commercial properties, and other businesses. It also offers comprehensive contract research organization (CRO) solutions, including one-stop, full-process services for drug R&D, such as Phase I to IV clinical trials, bioequivalence and pharmacokinetics testing, medical scienc… Read more